HAS2 facilitates glioma cell malignancy and suppresses ferroptosis in an FZD7 ‐dependent manner
Cancer Science · 2024
DOI: 10.1111/cas.16232 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Science, 2024. Verfasst von Zhiyuan Liu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China. Hauptthemen laut MEDLINE: Ferroptosis, Glioma, Frizzled Receptors, Hyaluronan Synthases. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: the Outstanding Young and Middle-aged Talents Support Program of the First Affiliated Hospital with Nanjing Medical University (Jiangsu Province Hospital), Jiangsu Province Capability Improvement Project through Science, Technology and Education.
Abstract (Originalsprache)
Glioma is the most common malignant tumor in the central nervous system, and it is crucial to uncover the factors that influence prognosis. In this study, we utilized Mfuzz to identify a gene set that showed a negative correlation with overall survival in patients with glioma. Gene Ontology (GO) enrichment analyses were then undertaken to gain insights into the functional characteristics and pathways associated with these genes. The expression distribution of Hyaluronan Synthase 2 ( HAS2 ) was explored across multiple datasets, revealing its expression patterns. In vitro and in vivo experiments were carried out through gene knockdown and overexpression to validate the functionality of HAS2 . Potential upstream transcription factors of HAS2 were predicted using transcriptional regulatory databases, and these predictions were experimentally validated using ChIP‐PCR and dual‐luciferase reporter gene assays. The results showed that elevated expression of HAS2 in glioma indicates poor prognosis. HAS2 was found to play a role in activating an antiferroptosis pathway in glioma cells. Inhibiting HAS2 significantly increased cellular sensitivity to ferroptosis‐inducing agents. Finally, we determined that the oncogenic effect of HAS2 is mediated by the key receptor of the WNT pathway, FZD7 .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurosurgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
- Department of Neurosurgery, Yang Zhong, Jiangsu Province People's Hospital, Yangzhou, China.
- Department of Neurosugery, Emergency General Hospital, Beijing, China.
ORCID-Profile: Zhiyuan Liu, Peng Zhao
Förderung
- the Outstanding Young and Middle-aged Talents Support Program of the First Affiliated Hospital with Nanjing Medical University (Jiangsu Province Hospital)
- Jiangsu Province Capability Improvement Project through Science, Technology and Education
Zitieren
APA
Liu, Z., Yu, K., Chen, K., Liu, J., Dai, K., & Zhao, P. (2024). HAS2 facilitates glioma cell malignancy and suppresses ferroptosis in an FZD7 ‐dependent manner. Cancer Science. https://doi.org/10.1111/cas.16232
Vancouver
Liu Z, Yu K, Chen K, Liu J, Dai K, Zhao P. HAS2 facilitates glioma cell malignancy and suppresses ferroptosis in an FZD7 ‐dependent manner. Cancer Science. 2024. doi:10.1111/cas.16232
BibTeX
@article{Liu2024,
author = {Liu, Zhiyuan and Yu, Kuo and Chen, Kaile and Liu, Jinlai and Dai, Kexiang and Zhao, Peng},
title = {HAS2 facilitates glioma cell malignancy and suppresses ferroptosis in an FZD7 ‐dependent manner},
journal = {Cancer Science},
year = {2024},
doi = {10.1111/cas.16232}
}
EUVIMED